NLRP3 and acute myeloid leukemia: The results demonstrated that AML patients with lower NLRP3 expression had a longer survival time and better OS (1-year OS: NLRP3low vs. NLRP3high 79% vs 44%, hazard ratio (HR) = 0.44, 95% confidence interval (CI): 0.24 to 0.79, P = 0.004, Figure 1B).